György M. Keserű
György M. Keserű
Verified email at - Homepage
Cited by
Cited by
Encyclopedia of Pharmaceutical Technology: Volume 6
J Swarbrick
CRC press, 2013
The role of ligand efficiency metrics in drug discovery
AL Hopkins, GM Keserü, PD Leeson, DC Rees, CH Reynolds
Nature reviews Drug discovery 13 (2), 105-121, 2014
The influence of lead discovery strategies on the properties of drug candidates
GM Keserü, GM Makara
nature reviews Drug Discovery 8 (3), 203-212, 2009
Expanding the medicinal chemistry synthetic toolbox
J Boström, DG Brown, RJ Young, GM Keserü
Nature Reviews Drug Discovery 17 (10), 709-727, 2018
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
A Douangamath, D Fearon, P Gehrtz, T Krojer, P Lukacik, CD Owen, ...
Nature communications 11 (1), 5047, 2020
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
MM Hann, GM Keserü
Nature reviews Drug discovery 11 (5), 355-365, 2012
Hit discovery and hit-to-lead approaches
GM Keserű, GM Makara
Drug discovery today 11 (15-16), 741-748, 2006
GPCRdb in 2021: integrating GPCR sequence, structure and function
AJ Kooistra, S Mordalski, G Pándy-Szekeres, M Esguerra, A Mamyrbekov, ...
Nucleic Acids Research 49 (D1), D335-D343, 2021
Design principles for fragment libraries: maximizing the value of learnings from pharma fragment-based drug discovery (FBDD) programs for use in academia
GM Keserű, DA Erlanson, GG Ferenczy, MM Hann, CW Murray, ...
Journal of medicinal chemistry 59 (18), 8189-8206, 2016
Impact of lipophilic efficiency on compound quality
A Tarcsay, K Nyíri, GM Keserű
Journal of medicinal chemistry 55 (3), 1252-1260, 2012
Optimization of virtual screening protocols: FlexX based virtual screening for COX-2 inhibitors reveals the importance of tailoring screen parameters
A Bauer, Z Kovári, GM Keserű
Journal of Molecular Structure: THEOCHEM 676 (1-3), 1-5, 2004
Thermodynamics guided lead discovery and optimization
GG Ferenczy, GM Keserű
Drug discovery today 15 (21-22), 919-932, 2010
Pharmacologic inhibition of STAT5 in acute myeloid leukemia
B Wingelhofer, B Maurer, EC Heyes, AA Cumaraswamy, A Berger-Becvar, ...
Leukemia 32 (5), 1135-1146, 2018
A high throughput luminescent assay for glycogen synthase kinase-3 β inhibitors
A Baki, A Bielik, L Molnár, G Szendrei, GM Keserü
Assay and drug development technologies 5 (1), 75-84, 2007
Contributions of molecular properties to drug promiscuity: miniperspective
Á Tarcsay, GM Keserű
Journal of medicinal chemistry 56 (5), 1789-1795, 2013
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods
GM Keserü
Bioorganic & medicinal chemistry letters 13 (16), 2773-2775, 2003
Recent advances in the prediction of blood–brain partitioning from molecular structure
M Lobell, L Molnár, GM Keserü
Journal of pharmaceutical sciences 92 (2), 360-370, 2003
Validity of ligand efficiency metrics
CW Murray, DA Erlanson, AL Hopkins, GM Keserü, PD Leeson, ...
ACS medicinal chemistry letters 5 (6), 616-618, 2014
Comparative evaluation of covalent docking tools
A Scarpino, GG Ferenczy, GM Keserű
Journal of Chemical Information and Modeling 58 (7), 1441-1458, 2018
Virtual fragment docking by Glide: a validation study on 190 protein− fragment complexes
M Sandor, R Kiss, GM Keserű
Journal of Chemical Information and Modeling 50 (6), 1165-1172, 2010
The system can't perform the operation now. Try again later.
Articles 1–20